Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Lung Neoplasms 5Myelodysplastic Syndromes 4Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Primary Myelofibrosis 2Lymphoma, Large B-Cell, Diffuse 2Hematologic Neoplasms 2Glioblastoma 2Breast Neoplasms 2Tumor Virus Infections 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Peritoneal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Plasma Cell 1

Interventions

Pemetrexed 2durvalumab 1Tretinoin 1Surgical Procedures, Operative 1Paclitaxel 1Observation 1Gemcitabine 1Cisplatin 1Carboplatin 1Bortezomib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Azacitidine × Thoracic × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡